Novartis vs Pfizer

Novartis was born from the colossal, record-breaking merger of two historic Swiss chemical and pharmaceutical giants: Ciba-Geigy and Sandoz. The new entity was immediately one of the largest pharmaceutical companies in the world. However, the company was initially bloated, with vast interests in everything from agricultural chemicals to food products, forcing the new management team to undertake a massive, multi-year process of selling off divisions to focus exclusively on pharmaceuticals.

In an attempt to redefine its strategic focus, Novartis executed a complex, multi-billion-dollar asset swap with GlaxoSmithKline (GSK). Novartis traded its oncology drug business for GSK’s vaccines and consumer products, effectively swapping one set of research priorities for another. It was a high-stakes, institutional-grade reorganization that signaled Novartis’s intent to focus its entire R&D budget on specialized, high-margin areas like immunology, neuroscience, and advanced cell therapy.

Continuing its decades-long trend of simplification, Novartis officially spun off its massive generic-drug division, Sandoz, into an independent company. This move was designed to free Novartis from the low-margin business of making cheap, generic knock-off drugs. The firm finally became a "pure-play" innovative pharmaceutical company, betting its entire valuation on its ability to invent novel, patent-protected therapies for complex, life-threatening illnesses.

Novartis poured billions into building world-class manufacturing facilities for cell and gene therapies—drugs that must be tailored to the individual patient’s biology. This was a massive technical hurdle, as the manufacturing process was notoriously difficult to scale. By perfecting these logistical and biological manufacturing workflows, Novartis aimed to become the "go-to" partner for the most complex therapies in the modern medical world.

By mid-2026, Novartis operates as a lean, focused, and high-performance pharmaceutical engine. With its generics business gone and its R&D streamlined, the Swiss giant is now an expert in high-value, patent-heavy therapeutic segments. The company’s ability to navigate the complex regulatory and manufacturing requirements of modern cell and gene medicine keeps it at the absolute pinnacle of the industry.

Charles Pfizer and his cousin Charles Erhart emigrated from Germany to New York in the 1840s and founded a fine chemicals business in Brooklyn in 1849 with $2,500 borrowed from Pfizer's father. Their first product was santonin — an antiparasitic compound used to treat intestinal worms, which were endemic among American children in the nineteenth century. They mixed it with almond-toffee flavouring to make it palatable. The product was a commercial success, establishing Pfizer as a specialty chemicals company.

During World War II, the U.S. government selected Pfizer to scale up penicillin production for Allied forces. Pfizer's fermentation expertise — developed over decades of making citric acid — proved crucial. The company developed a deep-tank fermentation process that dramatically increased penicillin yield. By June 1944, Pfizer was producing half of all penicillin made in the United States for the D-Day invasion. The wartime relationship with the U.S. government funded Pfizer's transition from chemicals to drugs.

Pfizer's researchers were conducting clinical trials on sildenafil — a drug intended to treat angina and hypertension — when male trial participants reported an unexpected side effect and were reluctant to return unused pills at the end of the trial. Pfizer pivoted the drug's development toward erectile dysfunction and launched Viagra in 1998. It was the first oral treatment for erectile dysfunction and generated $1 billion in its first year — the fastest pharmaceutical launch in history at the time. Pfizer's share price doubled.

Pfizer partnered with German biotechnology company BioNTech in 2020 to develop an mRNA vaccine against COVID-19. The vaccine was authorised for emergency use in the United Kingdom on December 2, 2020 — less than a year after the virus was first identified. Pfizer's COVID vaccine generated $36.8 billion in revenue in 2021 alone — the highest annual revenue from a single drug in pharmaceutical history. The mRNA technology used, previously unproven at scale, opened a new era in vaccine development and eventually earned BioNTech founders Uğur Şahin and Özlem Türeci the Nobel Prize in Medicine in 2023.

Pfizer reported full-year 2025 revenues of $62.6 billion — down 2% from 2024's $63.6 billion — as COVID vaccine and antiviral revenues continued to decline. Excluding COVID products, non-COVID revenue grew 6% operationally. Pfizer had delivered $4.5 billion in cost savings through 2025, acquired oncology company Seagen for $43 billion in 2023 to build a cancer drug pipeline, and acquired Metsera in November 2025. The company that had become the world's largest pharmaceutical company on the back of a pandemic vaccine was now managing the transition back to conventional pharma economics — where blockbusters took a decade to develop instead of nine months, and rarely generated $36 billion in a single year.